Capital 10X interviewed Khiron Life Sciences
Naprawa also details how Khiron’s operations are well-positioned to weather COVID-19, their plans to dominate all of Latin America, and how a healthy balance sheet and patient-first approach will help them reach their 2020 milestones.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.